UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 0-20852 ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or o ...

Part I [Item 1. Business](index=4&type=section&id=Item%201.%20Business) Ultralife Corporation designs and manufactures power and communications systems for government, defense, and commercial sectors globally - The company operates through two segments: **Battery & Energy Products** and **Communications Systems**, with performance reported at the gross profit level for each segment and operating expenses as Corporate charges[20](index=20&type=chunk) - On December 13, 2021, the company acquired **Excell Battery Group** to diversify commercial revenue and expand into new industrial markets like downhole drilling and medical devices[38](index=38&type=chunk) [Products, Services and Technology](index=9&type=section&id=Products%2C%20Services%20and%20Technology) The company's product portfolio includes lithium-based non-rechargeable and rechargeable batteries, charging systems, and military-grade RF amplifiers and integrated communication equipment - Battery & Energy Products include non-rechargeable lithium batteries (Li-MnO2, Li-CFx/MnO2, Li-SOCl2) and rechargeable Lithium-ion and Nickel Metal Hydride (NiMH) batteries and charging systems[21](index=21&type=chunk)[22](index=22&type=chunk) - Communications Systems products, sold under McDowell Research and AMTI brands, include RF amplifiers, power supplies, vehicle amplifier-adaptors (VAA), and integrated systems for military applications[53](index=53&type=chunk)[54](index=54&type=chunk)[55](index=55&type=chunk) [Sales and Marketing](index=11&type=section&id=Sales%20and%20Marketing) Ultralife employs a multi-channel sales strategy, with significant revenue from government contracts and a major defense contractor, leading to increased order backlog - A single major customer, **L3Harris Technologies**, accounted for **20% of total revenues in 2021** and **17% in 2020**[61](index=61&type=chunk) Sales by Region (FY 2020-2021) | Region | 2021 Sales (in thousands) | 2020 Sales (in thousands) | | :--- | :--- | :--- | | U.S. Customers | $48,819 | $62,255 | | Foreign Customers | $49,448 | $45,457 | Order Backlog by Segment (as of Dec 31) | Segment | 2021 Backlog (in thousands) | 2020 Backlog (in thousands) | YoY Change | | :--- | :--- | :--- | :--- | | Battery & Energy Products | $55,300 | $34,600 | +60% | | Communications Systems | $8,000 | $4,700 | +70% | [Manufacturing and Raw Materials](index=13&type=section&id=Manufacturing%20and%20Raw%20Materials) The company operates ISO-certified manufacturing facilities globally, facing supply chain risks from single-source suppliers, which impacted 2021 shipments and increased inventory - The company has **ISO 9001 and/or ISO 13485 certified manufacturing facilities** across North America, Europe, and Asia[78](index=78&type=chunk)[79](index=79&type=chunk) - Reliance on single or limited sources for certain raw materials led to **shipment delays in 2021**[82](index=82&type=chunk) Inventory Levels by Segment (as of Dec 31) | Segment | 2021 Inventory (in thousands) | 2020 Inventory (in thousands) | YoY Change | | :--- | :--- | :--- | :--- | | Battery & Energy Products | $25,677 | $20,714 | +24% | | Communications Systems | $7,512 | $7,479 | +0.4% | [Research and Development](index=16&type=section&id=Research%20and%20Development) Ultralife significantly invests in R&D, with expenditures totaling **$8.0 million in 2021**, and anticipates future increases to support new product initiatives R&D Expenditures (FY 2020-2021) | Category | 2021 (in thousands) | 2020 (in thousands) | | :--- | :--- | :--- | | Total R&D Expense | $8,042 | $7,316 | | Customer Sponsored R&D | $1,216 | $1,369 | - Future R&D expenditures are expected to **increase by 10% or more** over 2021 levels, driven by new battery and power solution development and Communications Systems initiatives[90](index=90&type=chunk) [Item 1A. Risk Factors](index=19&type=section&id=Item%201A.%20Risk%20Factors) The company faces multiple risks including COVID-19 impacts, customer concentration, military spending dependency, China operations, and supply chain disruptions - The COVID-19 pandemic negatively impacted 2021 operating results, with an estimated **$11.0 million reduction in sales** and **$4.5 million in operating profit** due to supply chain disruptions[117](index=117&type=chunk) - A significant portion of revenue is derived from key customers, with **L3Harris Technologies comprising 20% of total revenues in 2021**[119](index=119&type=chunk) - The company is highly dependent on U.S. and foreign military spending, which constituted **35% of revenues in 2021** and **42% in 2020**[121](index=121&type=chunk) - Operations in China are subject to unique risks, including regulatory changes, tariffs, trade restrictions, and potential disruptions from civil unrest or health crises[124](index=124&type=chunk) [Item 1B. Unresolved Staff Comments](index=30&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments - None[166](index=166&type=chunk) [Item 2. Properties](index=30&type=section&id=Item%202.%20Properties) Ultralife owns facilities in New York and Texas, and leases multiple global locations for its Battery & Energy Products and Communications Systems segments - The company owns facilities in Newark, NY (approx. **250,000 sq ft**) and Missouri City, TX (**69,000 sq ft**)[167](index=167&type=chunk) - Leased facilities include locations in Shenzhen, China (approx. **97,000 sq ft**), the United Kingdom (approx. **25,000 sq ft**), Canada/US for Excell (approx. **30,000 sq ft**), and Virginia Beach, VA (approx. **32,500 sq ft**)[167](index=167&type=chunk) [Item 3. Legal Proceedings](index=30&type=section&id=Item%203.%20Legal%20Proceedings) Ultralife received a **$1.593 million settlement** in 2020 from a lithium-ion batteries antitrust lawsuit, with no other material adverse legal matters identified - The company recognized a gain of **$1.593 million in 2020** from a settlement in the "In Re: Lithium-ion Batteries Antitrust Litigation" class action lawsuit, with funds collected in January 2021[168](index=168&type=chunk) [Item 4. Mine Safety Disclosures](index=30&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[170](index=170&type=chunk) Part II [Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=31&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Ultralife's common stock trades on NASDAQ under 'ULBI', with no history or future plans for cash dividends, as earnings are retained for operations and expansion - The company's common stock is listed on the **NASDAQ Global Market** under the symbol **'ULBI'**[173](index=173&type=chunk) - The company has never declared or paid cash dividends and does not anticipate paying any in the foreseeable future, intending to retain earnings for financing future operations[175](index=175&type=chunk) [Item 6. [RESERVED]](index=31&type=section&id=Item%206.%20%5BRESERVED%5D) This item is reserved and contains no information [Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=32&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Consolidated revenues decreased **8.8% to $98.3 million in 2021**, leading to a net loss of **$0.2 million**, primarily due to lower defense sales and supply chain disruptions, despite solid liquidity - For 2021, the company estimates that COVID-19 had a net negative impact of approximately **$11.0 million on sales** and **$4.5 million on operating income**[188](index=188&type=chunk) Consolidated Results of Operations (FY 2020-2021) | Metric (in thousands) | 2021 | 2020 | Change (%) | | :--- | :--- | :--- | :--- | | Total Revenues | $98,267 | $107,712 | (8.8%) | | Gross Profit | $24,642 | $29,159 | (15.5%) | | Operating Income | $35 | $5,701 | (99.4%) | | Net (Loss) Income Attributable to Ultralife | $(234) | $5,232 | N/A | | Diluted EPS | $(0.01) | $0.33 | N/A | - The decrease in government and defense sales was primarily due to the fulfillment of two large 2020 orders: a **$4.875 million order for BA-5390 batteries** and a **$5.680 million order for vehicle amplifier-adaptor systems**[190](index=190&type=chunk) - The company's liquidity remains solid, with **cash on hand of $8.4 million**, working capital of **$47.6 million**, and a current ratio of **3.5** as of December 31, 2021[197](index=197&type=chunk) [Item 7A. Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Ultralife is not required to provide this information - The company is not required to provide this information as it qualifies as a smaller reporting company[247](index=247&type=chunk) [Item 8. Financial Statements and Supplementary Data](index=45&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the company's audited consolidated financial statements for 2021 and 2020, including balance sheets, cash flows, and notes on accounting policies and the Excell acquisition Consolidated Balance Sheet Highlights (as of Dec 31) | Metric (in thousands) | 2021 | 2020 | | :--- | :--- | :--- | | Total Assets | $159,538 | $137,701 | | Total Liabilities | $41,795 | $20,778 | | Total Shareholders' Equity | $117,743 | $116,923 | Consolidated Statement of Cash Flows Highlights (Year Ended Dec 31) | Metric (in thousands) | 2021 | 2020 | | :--- | :--- | :--- | | Net cash provided by operating activities | $4,325 | $21,720 | | Net cash used in investing activities | $(26,333) | $(2,981) | | Net cash provided by (used in) financing activities | $19,642 | $(15,694) | - The acquisition of Excell on December 13, 2021, for a net purchase price of **$23.5 million**, was a major investing activity funded by cash and new debt facilities[315](index=315&type=chunk)[222](index=222&type=chunk) [Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=76&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants on accounting and financial disclosure - None[394](index=394&type=chunk) [Item 9A. Controls and Procedures](index=76&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2021, excluding the recently acquired Excell business - The CEO and CFO concluded that disclosure controls and procedures were **effective** as of December 31, 2021[395](index=395&type=chunk) - Management assessed internal control over financial reporting as **effective**, excluding the recently acquired Excell business from the scope of the assessment[398](index=398&type=chunk)[399](index=399&type=chunk) [Item 9B. Other Information](index=76&type=section&id=Item%209B.%20Other%20Information) The company reports no other information for this item - None[401](index=401&type=chunk) Part III [Item 10. Directors, Executive Officers and Corporate Governance](index=77&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information for this item is incorporated by reference from the company's 2022 Annual Meeting of Shareholders proxy statement - Information is incorporated by reference from the Proxy Statement[405](index=405&type=chunk) [Item 11. Executive Compensation](index=77&type=section&id=Item%2011.%20Executive%20Compensation) Information for this item is incorporated by reference from the company's 2022 Annual Meeting of Shareholders proxy statement - Information is incorporated by reference from the Proxy Statement[406](index=406&type=chunk) [Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=77&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Security ownership information is incorporated by reference, detailing equity compensation plan data including **1.3 million securities** for outstanding options Equity Compensation Plan Information (as of Dec 31, 2021) | Plan Category | Securities to be issued upon exercise of outstanding options, warrants and rights | Weighted-average exercise price | Securities remaining available for future issuance | | :--- | :--- | :--- | :--- | | Equity compensation plans approved by security holders | 1,306,824 | $6.87 | 941,986 | | Equity compensation plans not approved by security holders | - | - | - | | Total | 1,306,824 | $6.87 | 941,986 | [Item 13. Certain Relationships and Related Transactions, and Director Independence](index=77&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information for this item is incorporated by reference from the company's 2022 Annual Meeting of Shareholders proxy statement - Information is incorporated by reference from the Proxy Statement[410](index=410&type=chunk) [Item 14. Principal Accountant Fees and Services](index=77&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information for this item is incorporated by reference from the company's 2022 Annual Meeting of Shareholders proxy statement - Information is incorporated by reference from the Proxy Statement[411](index=411&type=chunk) Part IV [Item 15. Exhibits, Financial Statement Schedules](index=79&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists all financial statements and exhibits filed with the report, including key agreements and certifications - This section lists all financial statements, schedules, and exhibits filed with the report[412](index=412&type=chunk)[413](index=413&type=chunk)

Ultralife Corporation (NASDAQ:ULBI) Q4 2021 Earnings Conference Call February 3, 2022 8:30 AM ET Company Participants Jody Burfening - Investor Relations Mike Popielec - President and Chief Executive Officer Phil Fain - Chief Financial Officer Conference Call Participants Josh Sullivan - The Benchmark Company Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the ...

Ultralife Corporation (NASDAQ:ULBI) Q3 2021 Results Conference Call October 28, 2021 8:30 AM ET Company Participants Jody Burfening - MD and Principal Mike Popielec - President and CEO Phil Fain - Chief Financial Officer Conference Call Participants Gary Siperstein - Eliot Rose Wealth Management Josh Sullivan - The Benchmark Company Operator Good day, and welcome to this Ultralife Corporation's Third Quarter 2021 Earnings Release Conference Call. At this time, for opening remarks and introductions, I would ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 16-1387013 (State or other jurisd ...

Ultralife Corporation (NASDAQ:ULBI) Q2 2021 Earnings Conference Call July 29, 2021 8:30 AM ET Company Participants Jody Burfening - MD and Principal Mike Popielec - President and CEO Phil Fain - Chief Financial Officer Conference Call Participants Gary Siperstein - Eliot Rose Wealth Management Operator Good day, and welcome to the Ultralife Corporation Second Quarter 2021 Earnings Release Conference Call. At this time, for opening remarks and introductions, I would like to turn the call over to Ms. Jody Bur ...

Ultralife Corporation Investor Presentation Michael D. Popielec PRESIDENT & CEO Philip A. Fain CFO & TREASURER Updated July 29, 2021 1 IMPORTANT REMINDER – FORWARD LOOKING STATEMENTS This presentation may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 0-20852 ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 16-1387013 ( ...

Ultralife Corporation (NASDAQ:ULBI) Q1 2021 Earnings Conference Call April 29, 2021 8:30 AM ET Company Participants Jody Burfening - Investor Relations Mike Popielec - President and Chief Executive Officer Phil Fain - Chief Financial Officer Conference Call Participants Josh Sullivan - The Benchmark Company Gary Siperstein - Eliot Rose Wealth Management Operator Good day, and welcome to the Ultralife Corporation First Quarter 2021 Earnings Release Conference Call. At this time, for opening remarks, I'd like ...

Part I: Financial Information [Consolidated Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Consolidated%20Financial%20Statements%20(unaudited)) Q1 2021 revenues slightly increased to $26.0 million, net income decreased, and operating cash flow improved to $3.9 million [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Total assets slightly decreased to $136.4 million, liabilities fell, and shareholders' equity increased to $117.9 million Consolidated Balance Sheet Highlights (In Thousands) | Account | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Total Current Assets** | $63,520 | $64,496 | | **Total Assets** | **$136,390** | **$137,701** | | **Total Current Liabilities** | $16,635 | $18,706 | | **Total Liabilities** | **$18,529** | **$20,778** | | **Total Shareholders' Equity** | **$117,861** | **$116,923** | [Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) Q1 2021 revenues were flat at $26.0 million, while gross profit and operating income declined, leading to lower net income Q1 2021 vs. Q1 2020 Income Statement (In Thousands, except per share data) | Metric | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | **Revenues** | $25,973 | $25,814 | | **Gross Profit** | $6,978 | $7,334 | | **Operating Income** | $952 | $1,485 | | **Net Income Attributable to Ultralife** | $671 | $1,059 | | **Diluted EPS** | $0.04 | $0.07 | [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow significantly improved to $3.9 million in Q1 2021, resulting in a $3.0 million increase in cash balance Q1 2021 vs. Q1 2020 Cash Flow Summary (In Thousands) | Activity | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | **Net cash provided by (used in) operating activities** | $3,903 | $(365) | | **Net cash used in investing activities** | $(489) | $(445) | | **Net cash used in financing activities** | $(420) | $(322) | | **Increase (Decrease) in Cash** | $3,009 | $(1,296) | | **Cash, End of period** | $13,662 | $6,109 | [Notes to Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Notes detail debt compliance, effective tax rate changes, and segment performance, with Battery & Energy Products growing - The company is in full compliance with its debt covenants as of March 31, 2021, which include a consolidated fixed charge coverage ratio and a senior leverage ratio[26](index=26&type=chunk) - The effective tax rate for Q1 2021 was **24.2%**, compared to **22.9%** for Q1 2020, with the change primarily due to the geographic mix of earnings. The company has significant domestic NOL carryforwards of **$47.8 million**[45](index=45&type=chunk)[46](index=46&type=chunk) Segment Revenue (In Thousands) | Segment | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Battery & Energy Products | $22,111 | $20,761 | | Communications Systems | $3,862 | $5,053 | | **Total** | **$25,973** | **$25,814** | Revenue by Source (In Thousands) | Source | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Commercial | $14,345 (55%) | $14,802 (57%) | | Government/Defense | $11,628 (45%) | $11,012 (43%) | [Management's Discussion and Analysis (MD&A)](index=18&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) MD&A discusses slight revenue growth, gross margin decline, lower operating income, COVID-19 impact, and liquidity - The COVID-19 pandemic had an estimated net negative impact in Q1 2021, reducing sales by approximately **$2.0 million**, operating income by **$0.9 million**, and diluted EPS by **$0.04**[80](index=80&type=chunk) - Battery & Energy Products revenues grew **6.5%**, driven by a **32.2%** increase in medical sales and a **30.3%** increase in government/defense sales, but offset by a **30.0%** decrease in oil & gas market sales[90](index=90&type=chunk) - Communications Systems revenues decreased **23.6%**, primarily due to the completion of large delivery orders to the U.S. Army in 2020 that were not repeated in Q1 2021[91](index=91&type=chunk) - The company filed a shelf registration statement on Form S-3, effective April 2, 2021, allowing it to offer and sell up to **$100 million** in securities for general corporate purposes, including potential acquisitions[114](index=114&type=chunk) [Results of Operations](index=20&type=section&id=Results%20of%20Operations) Q1 2021 revenues increased slightly, driven by Battery & Energy Products growth, while gross margin declined - Consolidated gross margin decreased by **150 basis points** to **26.9%**, primarily reflecting sales mix, costs to transition new products to higher volume, and higher freight costs[83](index=83&type=chunk)[92](index=92&type=chunk) - Operating expenses increased by **3.0%** to **$6.0 million**, driven by a **6.4%** increase in R&D and a **9.6%** increase in sales and marketing, reflecting investments in new product development and market launches[84](index=84&type=chunk)[95](index=95&type=chunk) [Adjusted EBITDA and Adjusted EPS (Non-GAAP)](index=23&type=section&id=Adjusted%20EBITDA%20and%20Adjusted%20EPS) Non-GAAP Adjusted EBITDA decreased to $2.0 million and Adjusted EPS fell to $0.05 per diluted share in Q1 2021 Adjusted EBITDA Reconciliation (In Thousands) | Metric | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Net income attributable to Ultralife | $671 | $1,059 | | Add: Interest, Taxes, D&A, Stock Comp. | $1,341 | $1,463 | | **Adjusted EBITDA** | **$2,012** | **$2,522** | Adjusted EPS Reconciliation | Metric | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Diluted EPS (GAAP) | $0.04 | $0.07 | | Deferred tax provision per share | $0.01 | $0.01 | | **Adjusted Diluted EPS (Non-GAAP)** | **$0.05** | **$0.08** | [Liquidity and Capital Resources](index=25&type=section&id=Liquidity%20and%20Capital%20Resources) Cash increased by $3.0 million to $13.7 million due to strong operating cash flow and a litigation settlement - Cash increased by **$3.0 million** during the quarter, primarily due to **$3.9 million** generated from operations, which included net proceeds of **$1,593 thousand** from a class action lawsuit[109](index=109&type=chunk)[110](index=110&type=chunk) - As of March 31, 2021, the company had no amounts outstanding on its **$30 million** Revolving Credit Facility and was in full compliance with all debt covenants[115](index=115&type=chunk) [Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were effective, with no material changes to internal control over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of March 31, 2021[119](index=119&type=chunk) - No changes occurred during the fiscal quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[120](index=120&type=chunk) Part II: Other Information [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section lists key exhibits filed with the Form 10-Q, including CEO/CFO certifications and XBRL data - The report includes CEO and CFO certifications (Exhibits 31.1, 31.2, and 32) and financial statements formatted in Inline XBRL (Exhibit 101)[122](index=122&type=chunk) [Signatures](index=28&type=section&id=Signatures) The Form 10-Q was signed by the CEO and CFO on April 29, 2021 - The Form 10-Q was signed and authorized on April 29, 2021[127](index=127&type=chunk)